Phase 1b clinical trial will study effect of dosing methodology on immune response to intranasal anthrax vaccine GAITHERSBURG, Md., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc.(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Biomedical Advanced Rese... read more

Lund, Sweden, 10.00 am CET, 21 August 2019 – BONESUPPORT™, listed on Nasdaq Stockholm - an emerging leader in orthobiologics for the management of bone voids, announces that the patient enrollment schedule for the ongoing FORTIFY study is extended. Providing strong clinical evidence in s... read more

Uppsala, Sweden – August 20, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces it has entered into an exclusive agreement with GAIA AG (GAIA), a global leader in digital therapeutics that successfully launched it... read more

Stockholm – August 20, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) today announces that Klaas Bakker has been appointed as the new Chief Medical Officer (CMO) for Oncopeptides, starting in November. Johan Harmenberg has reached retirement age and as the company continues to expand i... read more

Oslo, Norway, 20 August 2019 Nordic Nanovector ASA (OSE: NANO) announces the appointment of Dr Lars Nieba as Chief Technology Officer and a member of the executive management team. Dr Nieba brings 20 years of leadership experience in the development of multiple pharmaceutical product ca... read more